{
    "organizations": [],
    "uuid": "767b9693e749baf346428e00a15a01ca88578016",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/04/20/business-wire-immunogen-announces-conference-call-to-discuss-its-first-quarter-2018-operating-results.html",
    "ord_in_thread": 0,
    "title": "ImmunoGen Announces Conference Call to Discuss Its First Quarter 2018 Operating Results",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 4, 2018 to discuss its first quarter operating results. Management also will provide a brief update on the business.\nConference Call Information\nTo access the live call by phone, dial 719-325-4799; the conference ID is 2070974. The call may also be accessed through the Investors section of the Company’s website, www.immunogen.com . Following the webcast, a replay of the call will be available at the same location through May 18, 2018.\nAbout ImmunoGen, Inc.\nImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. The Company’s lead product candidate, mirvetuximab soravtansine, is in the Phase 3 FORWARD I trial for FRα-positive platinum-resistant ovarian cancer, and is in the Phase 1b/2 FORWARD II trial in combination regimens for earlier-stage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC technology is also used in Roche's marketed product, Kadcyla ® , and in programs in development by Amgen, Bayer, Biotest, CytomX, Debiopharm, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at www.immunogen.com .\nKadcyla ® is a registered trademark of Genentech, a member of the Roche Group.\nView source version on businesswire.com : https://www.businesswire.com/news/home/20180420005134/en/\nFor Investors\nImmunoGen, Inc.\nSarah Kiely, 781-895-0600\nsarah.kiely@immunogen.com\nor\nFor Media\nImmunoGen, Inc.\nCourtney O'Konek, 781-895-0600\ncourtney.okonek@immunogen.com\nor\nFTI Consulting, Inc.\nRobert Stanislaro, 212-850-5657\nrobert.stanislaro@fticonsulting.com\nSource: ImmunoGen, Inc.",
    "published": "2018-04-20T16:00:00.000+03:00",
    "crawled": "2018-04-20T17:46:48.009+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "waltham",
        "business",
        "wire",
        "immunogen",
        "nasdaq",
        "imgn",
        "leader",
        "expanding",
        "field",
        "conjugate",
        "adcs",
        "treatment",
        "cancer",
        "today",
        "announced",
        "company",
        "host",
        "conference",
        "call",
        "et",
        "friday",
        "may",
        "discus",
        "first",
        "quarter",
        "operating",
        "result",
        "management",
        "also",
        "provide",
        "brief",
        "update",
        "business",
        "conference",
        "call",
        "information",
        "access",
        "live",
        "call",
        "phone",
        "dial",
        "conference",
        "id",
        "call",
        "may",
        "also",
        "accessed",
        "investor",
        "section",
        "company",
        "website",
        "following",
        "webcast",
        "replay",
        "call",
        "available",
        "location",
        "may",
        "immunogen",
        "immunogen",
        "biotechnology",
        "company",
        "develops",
        "targeted",
        "cancer",
        "therapeutic",
        "using",
        "proprietary",
        "adc",
        "technology",
        "company",
        "lead",
        "product",
        "candidate",
        "mirvetuximab",
        "soravtansine",
        "phase",
        "forward",
        "trial",
        "ovarian",
        "cancer",
        "phase",
        "forward",
        "ii",
        "trial",
        "combination",
        "regimen",
        "disease",
        "immunogen",
        "three",
        "additional",
        "product",
        "candidate",
        "two",
        "developed",
        "collaboration",
        "jazz",
        "pharmaceutical",
        "immunogen",
        "adc",
        "technology",
        "also",
        "used",
        "roche",
        "marketed",
        "product",
        "kadcyla",
        "program",
        "development",
        "amgen",
        "bayer",
        "biotest",
        "cytomx",
        "debiopharm",
        "lilly",
        "novartis",
        "sanofi",
        "takeda",
        "information",
        "company",
        "found",
        "kadcyla",
        "registered",
        "trademark",
        "genentech",
        "member",
        "roche",
        "group",
        "view",
        "source",
        "version",
        "http",
        "investor",
        "immunogen",
        "sarah",
        "kiely",
        "medium",
        "immunogen",
        "courtney",
        "fti",
        "consulting",
        "robert",
        "stanislaro",
        "source",
        "immunogen",
        "inc"
    ]
}